Company: WHWK
Filing Date: 2025-02-18
Form Type: DEFA14A
Source: 0001193125-25-028632
Chunk: 0

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-02-18
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting Material under §240.14a-12 |

AADI BIOSCIENCE, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 
 14a-6(i)(1) and 0-11.                                                          |

| PRESS RELEASE FOR DISTRIBUTION |

Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer Seasoned Oncology Leader Brings Extensive ADC Expertise to Support Company’s New Pipeline MORRISTOWN, NJ, February 18, 2025 – Aadi Bioscience, Inc. (NASDAQ: AADI) today announced the appointment of David Dornan, PhD as the Company’s Chief Scientific Officer (CSO). Dr. Dornan contributes more than two decades of experience in oncology drug discovery and development, with deep expertise in antibody-drug conjugates (ADCs) and other targeted cancer therapies. “David’s extensive experience in ADC development and track record of translating novel oncology discoveries into clinical programs make him an ideal leader as we seek to rapidly advance our newly in-licensedADC portfolio,” said David Lennon, PhD, President and CEO of Aadi Bioscience. “We are thrilled to welcome David to our growing ADC-experiencedteam, which also boasts board members from leading ADC companies, Behzad Aghazedeh, former CEO and Executive Chair of Immunomedics, and recently appointed Baiteng Zhao, PhD, co-founderand former Chairman and CEO of ProfoundBio.” Dr. Dornan joins Aadi at